Lisa Kern, MD, MPH
@lisakernmd.bsky.social
Associate Professor of Medicine. Health services researcher. @Weill Cornell Medicine
Public Health
39%
Medicine
25%
Reposted by Lisa M. Kern, Austin T. Robinson
Eric Topol
@erictopol.bsky.social
· Mar 10
Comparison of Research Spending on New Drug Approvals by the NIH vs the Pharmaceutical Industry
This cross-sectional study examines National Institutes of Health and pharmaceutical industry investments in recent drug approvals.
jamanetwork.com
99% of new medicines developed by the pharmaceutical industry depend on NIH research jamanetwork.com/journals/jam...
Reposted by Lisa M. Kern
The NIH’s drastic cut to indirect cost rates is a critical threat to U.S. research infrastructure
The drastic reduction in indirect costs is not a path to innovation or cost savings — it’s a threat to U.S.’s position as global leader in medical research.
www.statnews.com
Massive NIH cuts to research infrastructure threaten the foundation of U.S. research—putting our future at risk. We need innovation in funding, not dismantling our research engine. My take in @statnews: www.statnews.com/2025/02/08/n...
Reposted by Lisa M. Kern
Esther Choo
@choo.bsky.social
· Jan 24
Opinion | I’m a health researcher. NIH’s pause on research grants could have a devastating cost.
This is a potentially devastating event — not just for the scientific community, but for all Americans.
www.msnbc.com
An explainer about how health research funding happens and why this NIH funding cycle shutdown matters: www.msnbc.com/opinion/msnb...
All NIH study sections canceled indefinitely. This will halt science and devastate research budgets in universities.